Monograph Details
|
|
Immune System
> Immunization
|
|
HAVRIX |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Hepatitis A vaccine, inactivated 720 ELISA Units (EL.U.) per 0.5mL (pediatric), or 1440 EL.U. per 1mL (adult); susp for IM inj; aluminum adsorbed; contains neomycin (trace); preservative-free. |
| Indications |
|
Hepatitis A immunization. |
| Children |
|
Inject IM preferably at least 2 weeks before expected exposure. <12months: not recommended. 12months–18yrs: 720 EL.U. once IM; give booster dose 6–12months after initial course. |
| Adults |
|
Inject into deltoid, preferably at least 2 weeks before expected exposure. >18yrs: 1440 EL.U. once IM; give booster dose 6–12 months after initial course. |
| Contraindications |
|
Neomycin allergy. Previous hypersensitivity reaction to hepatitis A-containing vaccine. |
| Precautions |
|
Have epinephrine (1:1000) inj available. Fever. Bleeding disorders. Immunodeficiency (may have suboptimal response). If given with immune globulin, use separate syringe and different site. Latex allergy. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Immunosuppressives may reduce efficacy. Concomitant vaccines: see literature. |
| Adverse Reactions |
|
Inj site reactions, headache, fatigue, fever, malaise, anorexia, GI upset. |
| How Supplied |
Single-dose vials—10
Single-dose prefilled Tip-Lok syringes—5 (without needles) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
